Cancer therapy-related cardiac dysfunction: Collaboration with Oncology

Описание: This video is a recording of a presentation initially prepared for and presented at the Canadian Council of Cardiovascular Nurses' National Spring Conference hosted in Calgary, AB, in May 2024

Presenter: Coleen Power NP MN MPH
Cardio Oncology Program University Health Network - Toronto

Statement of purpose: The purpose of this abstract is to present the topic of cancer therapy-related cardiac dysfunction in women undergoing systemic therapy for HER 2 + breast cancer.

Description of the issue: Cancer therapy-related cardiac dysfunction (CTRCD) is a relatively common side effect of anthracycline and -2 targeted therapies affecting 9-20% of cancer survivors (Guglin, et al., 2019). CTRCD is a decrease in left ventricular ejection fraction (LVEF) by greater than 10% to an abnormal value, generally less than 53 % (Lyon, et al., 2022). The incidence of CTRCD can vary depending on the patient’s cardiac risk factors and cancer therapies. An overview of the risk factors, pathophysiology, diagnostics, treatment, and surveillance of CTRCD will be presented. Future directions in the nursing management of CTRCD will be reviewed.

Summary of conclusions: Collaboration between cardiology and oncology is critical in the early detection and treatment of CTRCD. Early identification and treatment of CTRCD and completion of cancer therapies can result in greater than 80% of patients recovering their heart function (Thavendiranathan, et al., 2021).

Description of significance and implications for practice. This early identification and treatment of CTRCD allow patients to continue their potentially cardiotoxic cancer therapies without interruption of treatment. Preventing interruptions in cancer therapies improves overall survival, decreases the risk of recurrence, and improves prognosis.